Case Reports in Oncological Medicine最新文献

{"title":"Isolated Metachronous Splenic Metastasis of Lung Adenocarcinoma: Long-Term Survival After Splenectomy.","authors":"Nina Wittlin, Martin Buess","doi":"10.1155/crom/1635762","DOIUrl":"https://doi.org/10.1155/crom/1635762","url":null,"abstract":"<p><p>Metastasis to the spleen is an uncommon finding in lung cancer and is typically associated with multivisceral disseminated disease. Isolated splenic metastasis in patients with lung cancer is exceedingly rare, with only 50 cases reported in the literature. We report a case of an asymptomatic, metachronous, isolated splenic metastasis in a 66-year-old female patient diagnosed 18 months after resection of lung adenocarcinoma. The patient underwent diagnostic and therapeutic splenectomy and remained tumor-free for 14 years. To our knowledge, this represents the longest reported survival following an isolated splenic metastasis from lung cancer. This case suggests that in well-selected patients with isolated splenic involvement, aggressive local therapy such as splenectomy can be curative and may lead to exceptional long-term survival.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"1635762"},"PeriodicalIF":0.6,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13088162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Report of Pancreatic Oligometastasis of Uterine Leiomyosarcoma.","authors":"Anne Cambrelin, Sydney Oesch, Brian Orr, Chelsea Wooster, David Lewin, Justin Harold","doi":"10.1155/crom/1838527","DOIUrl":"https://doi.org/10.1155/crom/1838527","url":null,"abstract":"<p><strong>Background: </strong>Uterine leiomyosarcoma (uLMS) is a rare, aggressive uterine malignancy with poor prognosis due to its early hematogenous spread, typically to the lungs and liver, and high recurrence rate. Pancreatic metastases are exceptionally rare, and isolated involvement of the pancreas is even more uncommon.</p><p><strong>Case: </strong>An 81-year-old patient was admitted after an unwitnessed fall and new neurologic symptoms, later diagnosed as a cerebellar stroke. Abdominopelvic imaging for urinary retention revealed a 9.9 × 15.1 × 18.8 - cm heterogeneous uterine mass and a 1.9-cm hypoenhancing lesion in the pancreatic head. Pelvic MRI findings suggested uLMS. Endoscopic ultrasound-guided biopsy confirmed the pancreatic lesion as metastatic leiomyosarcoma. No other sites of metastatic disease were found. Due to her extensive comorbidities and limited performance status, the patient ultimately elected for hospice care after being thoroughly counseled on her treatment options and multidisciplinary consultation.</p><p><strong>Conclusion: </strong>This case illustrates a rare instance of isolated pancreatic metastasis from primary uLMS, a presentation that can mimic primary pancreatic cancer. It emphasizes the need for a broad differential diagnosis, histologic confirmation, and individualized treatment planning in medically complex patients.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"1838527"},"PeriodicalIF":0.6,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual Pathway Inhibition in Patients With mRCC: A Case Series From Kuwait Highlighting the Role of Avelumab and Axitinib.","authors":"Mohamed Ashour, Mostafa El-Shahat","doi":"10.1155/crom/8007226","DOIUrl":"https://doi.org/10.1155/crom/8007226","url":null,"abstract":"<p><strong>Background: </strong>Renal cell carcinoma (RCC) accounts for approximately 3% of adult cancers and is characterized by aggressive behavior and early metastatic potential. The therapeutic paradigm of metastatic RCC (mRCC) has evolved from tyrosine kinase inhibitors (TKIs) alone to immune checkpoint inhibitors (ICIs) and ICI-TKI combinations. Avelumab, an anti-PD-L1 antibody, in combination with axitinib, a VEGFR-targeted TKI, has demonstrated efficacy in pivotal trials such as JAVELIN Renal 101.</p><p><strong>Objective: </strong>The objective of this study is to report the clinical outcomes of four patients with advanced mRCC and extensive metastases treated with avelumab with axitinib at the Kuwait Cancer Control Center (KCCC).</p><p><strong>Methods: </strong>This case series describes diagnostic imaging, treatment regimens, and disease progression in four patients. Imaging modalities included PET-CT and CT scans, performed at multiple intervals to assess therapeutic response, disease control, and treatment tolerability.</p><p><strong>Results: </strong>All patients demonstrated favorable radiological and clinical responses despite high metastatic burden and the presence of comorbidities, including disease regression or stable disease across multiple metastatic sites. Treatment was generally well tolerated, with no Grade III or IV toxicities recorded.</p><p><strong>Conclusion: </strong>This case series involving patients treated at KCCC demonstrates the real-world efficacy and tolerability of avelumab plus axitinib as a first-line option for metastatic renal cell carcinoma, even in patients with high metastatic burden, comorbidities, or prior treatment failure. Outcomes observed are consistent with JAVELIN Renal 101 trial findings, reinforcing the therapeutic value of dual immune and angiogenic pathway inhibition in advanced RCC care. Further investigation into biomarkers and patient selection may help optimize clinical outcomes across diverse populations.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"8007226"},"PeriodicalIF":0.6,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13067197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acral Lentiginous Melanoma With NRAS Mutation and Ocular Surface Toxicity Following Immunotherapy and Investigational KRASG12C Inhibitor: Case Report.","authors":"Elisah Huynh, Andrew Gregory, Peter Y Chang","doi":"10.1155/crom/7529882","DOIUrl":"https://doi.org/10.1155/crom/7529882","url":null,"abstract":"<p><p>We report the case of a patient with metastatic foot melanoma enrolled in a clinical trial of the anti-RAS agent RMC-6236 who developed chronic bilateral corneal epithelial defects and thinning, likely secondary to the systemic effects of targeted therapy. This case highlights the ocular surface toxicity associated with systemic anticancer therapies affecting rapidly dividing cells and the overall importance of multidisciplinary medical management of these systemic therapeutics.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"7529882"},"PeriodicalIF":0.6,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Not All Painless Jaundice in the Elderly Is Primary Pancreatic Cancer.","authors":"Manas Pustake, Virali Gulla, Ritwik Dey, Edwin Mendoza, Bhaswanth Bollu, Yagnapriya Chirrareddy, Lakshmi Kattamuri, Ramin Nassiry, Abhizith Deoker","doi":"10.1155/crom/2124659","DOIUrl":"https://doi.org/10.1155/crom/2124659","url":null,"abstract":"<p><p>Painless jaundice in elderly patients typically suggests primary pancreaticobiliary malignancy, but metastatic disease to the periampullary region represents an uncommon yet important differential diagnosis that can present with identical clinical features. We present a case of a 65-year-old woman with a history of Stage IIIB endometrial adenocarcinoma with known pelvic and mesenteric metastases, previously treated with salvage chemotherapy, who presented with 3 days of progressive painless jaundice, dark urine, and a year-long history of worsening diarrhea with significant weight loss. Laboratory evaluation revealed a cholestatic pattern of liver injury (total bilirubin 8.1 mg/dL and alkaline phosphatase 862 U/L), and imaging demonstrated new intra- and extrahepatic biliary ductal dilation with a spiculated duodenal mass infiltrating the ampulla and pancreatic head, along with bilateral hydroureteronephrosis from pelvic disease. Endoscopic retrograde cholangiopancreatography confirmed an infiltrative ampullary mass with successful biliary stent placement for decompression, resulting in improvement of hyperbilirubinemia. This case demonstrates that metastatic endometrial carcinoma can present as painless obstructive jaundice through duodenal and ampullary involvement, closely mimicking primary pancreatic adenocarcinoma both clinically and radiographically. Recognition of atypical metastatic patterns is essential for appropriate oncologic management, as treatment strategies and prognosis differ significantly between primary pancreaticobiliary malignancy and metastatic disease.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"2124659"},"PeriodicalIF":0.6,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13054824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Interaction Between Erlotinib and Itraconazole in a Patient With Non-Small Cell Lung Cancer.","authors":"Hayato Yokota, Satoshi Goshima, Yuji Okuda, Sho Sakamoto, Masahide Takeda, Kazuhiro Sato, Yumiko Akamine, Katsutoshi Nakayama, Masatomo Miura","doi":"10.1155/crom/7788444","DOIUrl":"https://doi.org/10.1155/crom/7788444","url":null,"abstract":"<p><strong>Introduction: </strong>Erlotinib (ERL) is metabolized primarily by cytochrome P450 (CYP) 3A4. We report a case of non-small cell lung cancer in which plasma ERL concentrations increased following coadministration of itraconazole (ITCZ).</p><p><strong>Case presentation: </strong>In this patient, a 67-year-old man receiving ERL 150 mg/day, the trough plasma concentration (<i>C</i> ₀) of ERL and its major metabolite, O-desmethyl ERL (OSI-420), increased following coadministration of ITCZ. The total clearance of ERL at steady state was 6.1 L/h. The mean <i>C</i> ₀ of ERL and OSI-420 were 437 and 47.1 ng/mL, respectively, and the <i>C</i> ₀ ratio of OSI-420/ERL was 0.108. With coadministration of oral ITCZ (200 mg/day capsule), the mean <i>C</i> ₀ of ERL and OSI-420 increased to 1124 and 166 ng/mL, respectively, and the mean <i>C</i> ₀ ratio of OSI-420/ERL increased to 0.147. The mean <i>C</i> ₀ of ITCZ and the sum of ITCZ and the active metabolite hydroxyitraconazole (OH-ITCZ) were 109 and 271 ng/mL, respectively. The mean <i>C</i> ₀ of ERL increased approximately 2.5-fold.</p><p><strong>Conclusion: </strong>Even at the relatively lower <i>C</i> ₀ of ITCZ (compared with the recommended target value), ITCZ coadministration increased the <i>C</i> ₀ of ERL. In patients with a sufficient ERL <i>C</i> ₀ of more than 500 ng/mL prior to ITCZ coadministration or patients exhibiting adequate absorption of oral ITCZ, the risk of ERL-related adverse events with ITCZ coadministration may increase due to further elevation of the ERL <i>C</i> ₀. Therefore, when ERL is coadministered with ITCZ, careful monitoring for adverse effects and appropriate dose adjustments are required, considering potential changes in ERL concentrations. Management using the <i>C</i> ₀ of ERL and ITCZ may be necessary.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"7788444"},"PeriodicalIF":0.6,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13054510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147637993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Pulmonary NUT Carcinoma: A Case Illustration of Therapeutic Challenges and Review of Emerging Targeted Therapies.","authors":"Jessica Y Bae, Xiang Yu Gao, Josephine K Dermawan, Jessica A Hellyer","doi":"10.1155/crom/4908133","DOIUrl":"https://doi.org/10.1155/crom/4908133","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary NUT carcinoma is a rare but highly aggressive malignancy with poor prognosis. It typically affects younger patients with no smoking history. Given its rapid progression, it is crucial to consider it as a differential diagnosis in a poorly differentiated thoracic mass to ensure timely diagnosis and management.</p><p><strong>Case presentation: </strong>We report a case of primary pulmonary NUT carcinoma diagnosed in a 59-year-old male with a never-smoking history during routine screening for possible occupational asbestos exposure. The preliminary diagnosis of metastatic keratinizing squamous cell carcinoma was later reclassified as NUT carcinoma by immunohistochemistry. Next generation sequencing of ctDNA showed <i>CDKN2A</i> mutation. The therapeutic course was complicated by several hypersensitivity reactions to first line treatments. Due to rapidly deteriorating clinical status, the patient was no longer eligible for a BET inhibitor clinical trial and died approximately 5 months after diagnosis.</p><p><strong>Conclusion: </strong>Due to its rarity and poor therapeutic response, there is currently no established standard of treatment for pulmonary NUT carcinoma. Timely and accurate diagnosis remains challenging due to its nonspecific presentation and rarity, resulting in low clinical suspicion, especially in patients outside the typical demographic. Common first-line treatments include platinum-based regimens in combination with etoposide or paclitaxel. Several clinical trials of BET and histone deacetylase inhibitors are active, and clinicians are encouraged to enroll patients to maximize survival outcomes.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"4908133"},"PeriodicalIF":0.6,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13054950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147637995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testicular Embryonal Carcinoma With Retroperitoneal Metastasis and Normal AFP and HCG: A Case Report.","authors":"Panpan Teng, Mingxi Yang, Shang Song","doi":"10.1155/crom/9821202","DOIUrl":"https://doi.org/10.1155/crom/9821202","url":null,"abstract":"<p><p>Testicular germ cell tumors are common malignant tumors in young men, among which embryonal carcinoma, as an important subtype of non-seminomatous germ cell tumors, is usually accompanied by elevated serum tumor markers. This case report describes a 24-year-old male patient with testicular embryonal carcinoma and retroperitoneal lymph node metastasis, yet with persistently normal serum markers, posing significant diagnostic challenges. Diagnosis was ultimately confirmed through imaging, histopathology, and immunohistochemical analysis. The patient underwent radical orchiectomy followed by standard bleomycin, etoposide, and cisplatin (BEP) chemotherapy and showed no recurrence at 12-month follow-up. This case highlights the necessity of a multidisciplinary diagnostic approach, integrating clinical evaluation, imaging, and immunohistochemistry, to ensure accurate diagnosis, particularly in marker-negative presentations. It also confirms the efficacy of established treatment protocols and emphasizes the importance of heightened clinical vigilance and long-term follow-up for such atypical cases.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"9821202"},"PeriodicalIF":0.6,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13058434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147644019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the Setting of Vinblastine and Dacarbazine Shortages: A Case Series.","authors":"Ishwarya Satyavarapu, Noah Giese, Prakruti Gandhi, Godsfavour Umoru, Ethan A Burns, Sai Ravi Pingali","doi":"10.1155/crom/5446464","DOIUrl":"https://doi.org/10.1155/crom/5446464","url":null,"abstract":"<p><strong>Purpose: </strong>Oncology drug shortages have significant implications on patient care, particularly with curative intent therapeutic strategies. This case series highlights strategic management for patients with classical Hodgkin lymphoma (cHL) in the setting of recent dacarbazine and vinblastine shortages without compromising outcomes.</p><p><strong>Summary: </strong>cHL is a highly curable malignancy with initial treatment strategies incorporating chemotherapy, radiation therapy, chemoradiotherapy, or chemoimmunotherapy. The standard of care for patients with cHL includes a backbone of doxorubicin, vinblastine, and dacarbazine (AVD) based therapies in combination with either bleomycin, brentuximab vedotin (BV), or nivolumab. However, in 2023, critical shortages of dacarbazine and vinblastine led to rationing of these agents, raising concerns for a paucity of clear management strategies in patients with cHL. The three patients described in this case series received lower cumulative doses of standard chemotherapy as opposed to alternative therapies without compromising outcomes.</p><p><strong>Conclusion: </strong>Treatment of advanced stage cHL during dacarbazine and vinblastine shortage requires careful consideration of alternative therapies and collaborative effort among healthcare professionals. This case series highlights that with a response-added approach and vigilant monitoring, effective cancer treatment strategies may be implemented despite drug shortages.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"5446464"},"PeriodicalIF":0.6,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Mohs Micrographic Surgery for Facial Porocarcinoma in an Adolescent and Literature Review.","authors":"Wenwen Jing, Weiqi Lei, Zhicheng Gong, Pingxiu He, Yong Ai, Junwu Yang","doi":"10.1155/crom/9929153","DOIUrl":"https://doi.org/10.1155/crom/9929153","url":null,"abstract":"<p><strong>Introduction: </strong>Eccrine porocarcinoma (EPC), the most common malignant tumor of the eccrine sweat glands, accounts for approximately 0.005%-0.01% of all skin malignancies. However, a standard treatment for EPC is currently lacking. Many previous studies demonstrated that it mainly occurs in the elderly and is extremely rare in adolescents. Here, we report a case of Mohs micrographic surgery for facial porocarcinoma in an adolescent patient.</p><p><strong>Case: </strong>A 19-year-old male adolescent was admitted to the hospital with a 6-month history of a gradually enlarging itchy brown mass in the right nasolabial sulcus. After a pathological examination of the skin biopsy in the outpatient department, he was admitted to the hospital for Mohs surgery. Postoperatively, the wound defect was repaired using a local flap.</p><p><strong>Results: </strong>The patient recovered well after the surgery, and no recurrence was observed after 35 months of follow-up.</p><p><strong>Conclusion: </strong>Our case demonstrated the effective early diagnosis and surgical intervention of EPC.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"9929153"},"PeriodicalIF":0.6,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}